ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection
Trial details
- Registry ID
- NCT07513285
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as ACX-362E
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile InfectionNCT07513285 | ACXP | Phase 2 | Recruiting | 2027-09-29Estimated |
| ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile InfectionNCT04247542 | ACXP | Phase 2 | Completed | 2023-10-03Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |